Pharma Heads Pass Leadership Baton
BioSpectrum Asia|BioSpectrum Asia Dec 2023
The pharmaceutical industry is evaluating and adapting to the Great Reset, set in motion back in 2020. One key strategy in this regard has been the change of management structure, with several high-profile leadership changes in 2023. As the euphoria of pandemic-induced record revenues subsided in 2023, the pharmaceutical industry had to reevaluate its strategies and has undergone significant structural changes. Companies adapted their approaches, implementing measures such as job cuts, mergers and acquisitions M&A), and a comprehensive overhaul of top management to navigate the evolving landscape effectively. Big Pharma elites, including Pfizer, Sanofi, Novartis, Astellas, among others, have announced a slew of leadership changes in recent times. Let’s explore these further.
Ayesha Siddiqui
Pharma Heads Pass Leadership Baton

In March 2023, Pfizer announced a $43 billion merger with Seagen, one of the most substantial M&A deals in recent times. Fast-forwarding to July 2023, Pfizer had already initiated strategic leadership changes, preparing itself for the impending mega-merger.

Dr Chris Boshoff joined Pfizer’s executive leadership team as chief oncology research and development officer and executive vice president (VP). Boshoff will be the single point of accountability for the entire oncology pipeline – from discovery to early and late-phase clinical development. Previously, Dr Boshoff oversaw clinical research and product development activities for Pfizer’s oncology portfolio. In addition to his expanded role, Dr Boshoff is leading the integration planning for Seagen’s medicines and team. 

Chief Scientific Officer (CSO) Dr Mikael Dolsten will expand his role to become CSO and president of R&D. William Pao, chief development officer and Executive VP, is leaving the company to pursue new opportunities outside. Pfizer believes the changes will benefit the company in its current stand-alone structure, and also aligns with Pfizer’s vision for the potentially combined organisations.

Novartis recently witnessed a series of leadership changes. Marie-France Tschudin, the president of innovative medicines international and chief commercial officer, has chosen to leave the company after nearly seven years. Consequently, she will step down from the Executive Committee of Novartis (ECN). Dr Patrick Horber, (Former VP, AbbVie) has been appointed as the new president, International. Dr Horber will also assume a position on ECN.

Denne historien er fra BioSpectrum Asia Dec 2023-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

Denne historien er fra BioSpectrum Asia Dec 2023-utgaven av BioSpectrum Asia.

Start din 7-dagers gratis prøveperiode på Magzter GOLD for å få tilgang til tusenvis av utvalgte premiumhistorier og 9000+ magasiner og aviser.

FLERE HISTORIER FRA BIOSPECTRUM ASIASe alt
Prof. Christian Wolfrum to join NTU as Deputy President and Provost
BioSpectrum Asia

Prof. Christian Wolfrum to join NTU as Deputy President and Provost

Nanyang Technological University, Singapore (NTU Singapore) has announced that Professor Christian Wolfrum, an eminent biomedical scientist, will be joining the University as the next Deputy President and Provost.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Japan suggests addition of PVA into drugs for strong antitumour activity
BioSpectrum Asia

Japan suggests addition of PVA into drugs for strong antitumour activity

Treatment for more advanced and difficult-to-treat head and neck cancers can be improved with the addition of polyvinyl alcohol (PVA), the same ingredient used in children's glue.

time-read
1 min  |
BioSpectrum Asia Feb 2025
"Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"
BioSpectrum Asia

"Demand for skilled medtech professionals in the Asia Pacific region is growing rapidly"

2024 saw Japanese medtech firm Olympus receiving approval for the company's first cloud-based AI endoscopy devices in the US and Europe, marking a significant milestone in Olympus' efforts to enhance clinical outcomes and operational efficiency in endoscopy, paving the way to launch its upcoming endoscopy solution, the “Intelligent Endoscopy Ecosystem”.

time-read
5 mins  |
BioSpectrum Asia Feb 2025
BeiGene names Giancarlo Benelli as Head of Europe biz
BioSpectrum Asia

BeiGene names Giancarlo Benelli as Head of Europe biz

BeiGene, a Hong Kong-headquartered oncology company that intends to change its name to BeOne Medicines Ltd., has announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Korea develops innovative injectable adhesive hydrogel for bone regeneration
BioSpectrum Asia

Korea develops innovative injectable adhesive hydrogel for bone regeneration

A research team from South Korea-based Pohang University of Science and Technology or POSTECH's Department of Chemical Engineering and Graduate School of Convergence Science and Technology, along with the Department of Chemical Engineering, has developed an innovative injectable adhesive hydrogel for bone regeneration.

time-read
1 min  |
BioSpectrum Asia Feb 2025
When Clinical Trials Suffer From 'Complicated' Interactions
BioSpectrum Asia

When Clinical Trials Suffer From 'Complicated' Interactions

Diversity in culture, language, and data gathering methods will further increase the difficulty of clinical trials as they become more international, particularly with the growing number of sites being employed across China, Japan, South Korea, and India.

time-read
5 mins  |
BioSpectrum Asia Feb 2025
Dr Krishna M Ella receives prestigious INSA India fellowship
BioSpectrum Asia

Dr Krishna M Ella receives prestigious INSA India fellowship

Dr Krishna Ella, a distinguished scientist, co-founder and Executive Chairman of Bharat Biotech International, has been recognised with the prestigious India Fellowship of the Indian National Science Academy (INSA) for the year 2025, for his contributions to new knowledge, discoveries, development of new vaccine technologies, noteworthy improvement in existing technologies.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Bruker launches infrared imaging microscope for pharma and life science research
BioSpectrum Asia

Bruker launches infrared imaging microscope for pharma and life science research

US-based Bruker Corporation has announced the launch of the LUMOS II ILIM, a quantum cascade laser (QCL) based infrared (IR) imaging microscope.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities
BioSpectrum Asia

Qiagen increases QIAcuity digital PCR high-order multiplexing capabilities

Qiagen has announced a significant increase in the powerful capabilities of its QIAcuity Digital PCR (dPCR) system with a more than two-fold increase in the number of targets that can be simultaneously analysed from a single biological sample.

time-read
1 min  |
BioSpectrum Asia Feb 2025
Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers
BioSpectrum Asia

Repligen unveils advanced UV-based Variable Pathlength Technology system for biopharma manufacturers

US-based Repligen Corporation has announced the commercial launch of its CTech SoloVPE PLUS System, the most advanced UV-based Variable Pathlength Technology system now available to biopharmaceutical manufacturers.

time-read
1 min  |
BioSpectrum Asia Feb 2025